<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427271</url>
  </required_header>
  <id_info>
    <org_study_id>02-353</org_study_id>
    <nct_id>NCT00427271</nct_id>
  </id_info>
  <brief_title>Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <brief_summary>
    <textblock>
      Research design: randomized, double-blind, placebo-controlled crossover study to evaluate the
      putative interference of low-dose aspirin (for 8 weeks) on enalapril antiproteinuric
      properties in microalbuminuric type 2 diabetes mellitus patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research design: randomized, double-blind, placebo-controlled crossover study Patients:
      Microalbuminuric (urinary albumin excretion [UAE]30-300 mg/d)type 2 diabetes mellitus
      patients without ischemic heart disease or peptic ulcer Aim:To evaluate the putative
      interference of low-dose aspirin (300 mg/d)for 8 weeks)on enalapril antiproteinuric
      properties in microalbuminuric type 2 diabetes mellitus patients Study protocol:Crossover
      randomization to 8 weeks of enalapril 10 mg/d plus aspirin (300 mg/d) or plus placebo, and a
      6-week washout period. Measurement of UAE (immunoturbidimetry) and glomerular filtration rate
      (51Cr-EDTA), blood pressure and metabolic control at baseline and at the end of each period.

      Statistical analyses: Bland&amp;Altman analyses for crossover trials.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2003</start_date>
  <completion_date>January 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary albumin excretion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>glomerular filtration rate</measure>
  </primary_outcome>
  <enrollment>20</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Microalbuminuria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus microalbuminuria

        Exclusion Criteria:

          -  ischemic heart disease peptic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo G Camargo</last_name>
    <role>Study Director</role>
    <affiliation>Programa de Pós-graduação em Ciências Médicas: Endocrinologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra P Silveiro</last_name>
    <phone>55 51 33325188</phone>
    <email>sandrasilveiro@terra.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Aelgre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>900035900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra P Silveiro, MD</last_name>
      <phone>55 51 33325188</phone>
      <email>sandrasilveiro@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Sandra P Silveiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo G Camargo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <last_update_submitted>January 26, 2007</last_update_submitted>
  <last_update_submitted_qc>January 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2007</last_update_posted>
  <keyword>aspirin</keyword>
  <keyword>enalapril</keyword>
  <keyword>microalbuminuria</keyword>
  <keyword>glomerular filtration rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

